The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Kirn David since 2022.
This trader's CIK number is 1834021.
At the time of last reporting, Kirn David was the Chief Executive Officer of 4d Molecular Therapeutics, Inc.. (stock ticker symbol FDMT).
Also see all insider trading activities at 4d Molecular Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2024 | FDMT | 0 | $0 | 225,853 | $5,156,886 | 25,853 | $381,587 |
| 2023 | FDMT | 0 | $0 | 53,970 | $1,106,878 | 0 | $0 |
| 2022 | FDMT | 0 | $0 | 86,877 | $2,027,326 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-07-10 | FDMT | Option Ex | 12,923 | 15.10 | 195,137 |
| 2024-07-10 | FDMT | Sale | 12,923 | 22.49 | 290,599 |
| 2024-06-24 | FDMT | Sale | 12,930 | 23.10 | 298,708 |
| 2024-06-24 | FDMT | Option Ex | 12,930 | 14.42 | 186,450 |
| 2024-02-08 | FDMT | Sale | 92,001 | 27.13 | 2,495,803 |
| 2024-01-23 | FDMT | Sale | 5,696 | 18.41 | 104,851 |
| 2023-12-15 | FDMT | Sale | 28,632 | 17.27 | 494,446 |
| 2024-01-04 | FDMT | Sale | 40,732 | 20.31 | 827,185 |
| 2024-01-05 | FDMT | Sale | 28,237 | 19.83 | 560,052 |
| 2023-12-18 | FDMT | Sale | 4,702 | 18.13 | 85,242 |
| 2023-02-21 | FDMT | Sale | 17,997 | 21.21 | 381,734 |
| 2023-02-22 | FDMT | Sale | 16,449 | 20.22 | 332,664 |
| 2023-01-19 | FDMT | Sale | 10,899 | 20.03 | 218,350 |
| 2023-01-20 | FDMT | Sale | 8,625 | 20.19 | 174,130 |
| 2022-12-15 | FDMT | Sale | 32,933 | 23.85 | 785,320 |
| 2022-12-16 | FDMT | Sale | 53,944 | 23.02 | 1,242,006 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Kirn David (Chief Executive Officer of 4d Molecular Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.